Scilex (SCLX) - Rasio rega marang prakiraan pendapatan

Logo perusahaan publik Scilex Holding Company (SCLX)

The risks of narrow specialization for Scilex Holding Company are mitigated by the successful market launch of patented patches. The projected market cap-to-revenue ratio visualizes this trend, where 0.10 expresses the current value of the metric. The financial foundation relies on the commercialization of ZTlido and pain-relief injections. A positive trend is fueled by demand for non-opioid treatments and the progress of the drug SP-102.

SCLX scilexholding.com: Rasio rega marang prakiraan pendapatan ing interval 28.04.2023 - 18.11.2026

Rincian analitis perusahaan Scilex Holding Company

- rega saiki lan proyeksi nilai saham:
Pambiji fundamental perusahaan:Scilex Holding SCLX
Sampel barang Scilex Holding Company

Forward P/S measures market capitalization relative to projected revenue, allowing investors to assess an asset's degree of overvaluation during periods of high volatility. By analyzing the expected P/S of Scilex Holding Company (SCLX), one can determine a minimum-risk entry point, given that stable demand for SCLX pain medications ensures predictable cash flows regardless of economic cycles.

Pesaing utama

Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Xenon Pharmaceuticals Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Viking Pharma|SUPN: Rega forward marang dodolan|Multiplikator Forward P/S CPRX|Multiplikator Forward P/S denalitherapeutics.com (DNLI)|Multiplikator Forward P/S HRMY (Harmony Biosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Biohaven (BHVN)|Amylyx Corp - Multiplikator Forward P/S|TRVI - Multiplikator Forward P/S|Praxis Precision Medicines Inc (PRAX) - Rasio rega marang prakiraan pendapatan|AVXL - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CeriBell|Multiplikator Forward P/S Prothena Corporation plc|Rasio rega marang prakiraan pendapatan Alector Therapeutics (ALEC)|Annexon Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan omeros.com OMER|neurogene.com (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|acimmune.com - Multiplikator Forward P/S|Voyager Therapeutics Inc (VYGR) - Multiplikator forward rega marang pendapatan|Neumora Corp (NMRA) - Rasio rega marang prakiraan pendapatan|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S